Initial treatment of pediatric differentiated thyroid cancer: a review of the current risk-adaptive approach

Area of Science:

• Endocrinology
• Pediatric Oncology
• Surgical Oncology

Background:

• Differentiated thyroid cancer (DTC) is a rare pediatric malignancy, comprising 1.4% of childhood cancers.
• Pediatric DTC exhibits distinct diagnostic, biological, and therapeutic characteristics compared to adult DTC.
• Optimal management strategies for pediatric DTC remain an area of ongoing research and discussion.

Purpose of the Study:

• To summarize the current understanding and consensus on the management of differentiated thyroid cancer in children.
• To highlight the unique aspects of pediatric DTC compared to adult forms.
• To emphasize the importance of specialized care for pediatric DTC.

Main Methods:

• Review of existing literature and clinical guidelines on pediatric differentiated thyroid cancer.
• Analysis of treatment modalities including surgery and radioactive iodine therapy.
• Emphasis on the multidisciplinary approach involving specialized pediatric endocrine surgeons and nuclear medicine experts.

Main Results:

• Differentiated thyroid cancer in children is uncommon and presents differently than in adults.
• Key treatment components include total thyroidectomy, central lymph node dissection for nodal metastases, and potential iodine-131 radiotherapy.
• There is a consensus on the necessity of treatment by experienced specialists.

Conclusions:

• Differentiated thyroid cancer in children requires specialized management distinct from adult protocols.
• Multidisciplinary expert care, including high-volume endocrine surgeons and experienced radioactive iodine specialists, is crucial.
• While some management aspects are debated, consensus supports specialized, comprehensive treatment for pediatric DTC.